Endocrine Archives - Oncology Central Oncology Central

Must read

11 Feb 2019 Journal Articles
Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis

15 Jan 2019 Endocrine
The safety and efficacy of lenvatinib in advanced thyroid cancer patients: a Phase II trial
9 Nov 2018
NICE recommends new first-line treatment Lenvima against advanced liver cancer
5 Nov 2018 Endocrine
NCRI 2018: HiLo trial suggests low risk thyroid cancer patients can receive lower doses of radiation
13 Aug 2018
Blood test could detect kidney cancer up to 5 years earlier
7 Aug 2018 Endocrine
Exploring the Thyroid Imaging Reporting and Data System (TI-RADS): an interview with Franklin Tessler
3 Aug 2018
FDA approves first-in-class treatment for rare adrenal tumors

Must watch

Stay up to date

Upcoming event

Gastrointestinal Cancers Symposium

January 17, 2019 – January 19, 2019

CA, USA

View all

Upcoming event

International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer

February 9, 2019 – February 11, 2019

Kyoto, Japan

View all

Tweets

Oncology Central @OncologyCentral·

The US Centers for Medicare and Medicaid Services have recently announced that they will cover the FDA approved #CART therapy under the category of ‘Coverage with Evidence Development’. Click the image below for the full news story: https://t.co/mpbfWVIlPe

View all

Jobs

Connecting talent with opportunity. View our featured jobs

View all

Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis

The safety and efficacy of lenvatinib in advanced thyroid cancer patients: a Phase II trial

NICE recommends new first-line treatment Lenvima against advanced liver cancer

NCRI 2018: HiLo trial suggests low risk thyroid cancer patients can receive lower doses of radiation

Blood test could detect kidney cancer up to 5 years earlier

Exploring the Thyroid Imaging Reporting and Data System (TI-RADS): an interview with Franklin Tessler

FDA approves first-in-class treatment for rare adrenal tumors

Born to be bad: researchers identify the genetic roots of ‘killer’ kidney cancers

Cyramza® meets primary endpoint of overall survival in liver cancer study

Advancing treatment options for medullary thyroid cancer: an interview with Jonathan Wadsley

Endogenous virus expression could help predict RCC responsiveness to immune checkpoint therapy

Phase III CELESTIAL trial of cabozantinib demonstrates significant overall survival benefit in HCC patients

Thyroid cancer in adolescents and young adults

ESMO WCGI: Promising initial results reported for immunotherapy for HCC

Sonogram scoring system developed for thyroid nodules to reduce biopsy rates

Low survival rates observed for specific thyroid cancers following bone metastasis

Signaling pathways in medullary thyroid carcinoma: therapeutic implications

Advances in diagnosis and management of familial pituitary adenomas

Resection of primary gastroenteropancreatic neuroendocrine tumors in the presence of irresectable liver metastases

Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma

Interplay of genetic and epigenetic alterations in hepatocellular carcinoma

Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives

Optimising Dose to Tumour with Selective Internal Radiation Therapy (SIRT)

Login

Endocrine

Must read

Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis

The safety and efficacy of lenvatinib in advanced thyroid cancer patients: a Phase II trial

NICE recommends new first-line treatment Lenvima against advanced liver cancer

NCRI 2018: HiLo trial suggests low risk thyroid cancer patients can receive lower doses of radiation

Blood test could detect kidney cancer up to 5 years earlier

Exploring the Thyroid Imaging Reporting and Data System (TI-RADS): an interview with Franklin Tessler

FDA approves first-in-class treatment for rare adrenal tumors

Must watch

Born to be bad: researchers identify the genetic roots of ‘killer’ kidney cancers

Cyramza® meets primary endpoint of overall survival in liver cancer study

Advancing treatment options for medullary thyroid cancer: an interview with Jonathan Wadsley

Endogenous virus expression could help predict RCC responsiveness to immune checkpoint therapy

Phase III CELESTIAL trial of cabozantinib demonstrates significant overall survival benefit in HCC patients

Thyroid cancer in adolescents and young adults

ESMO WCGI: Promising initial results reported for immunotherapy for HCC

Sonogram scoring system developed for thyroid nodules to reduce biopsy rates

Low survival rates observed for specific thyroid cancers following bone metastasis

Signaling pathways in medullary thyroid carcinoma: therapeutic implications

Advances in diagnosis and management of familial pituitary adenomas

Resection of primary gastroenteropancreatic neuroendocrine tumors in the presence of irresectable liver metastases

Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma

Interplay of genetic and epigenetic alterations in hepatocellular carcinoma

Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives

Optimising Dose to Tumour with Selective Internal Radiation Therapy (SIRT)

Stay up to date

Oncology Central Newsletter